Year All2024202320222021202020192018201720162015 Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus April 17, 2024 Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma April 8, 2024 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 1, 2024 Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer March 25, 2024 Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 19, 2024 Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma March 13, 2024 Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 March 7, 2024 Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 4, 2024 Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones January 4, 2024 Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting December 10, 2023
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus April 17, 2024
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma April 8, 2024
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 19, 2024
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma March 13, 2024
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 March 7, 2024
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones January 4, 2024
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting December 10, 2023
